Search Results
ESMO 2020 Highlights on 1st line lorlatinib for ALK+ NSCLC: The CROWN Study
ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study
ESMO 2020 Highlights on durability of clinical benefit and biomarkers with AMG510 in NSCLC
Lorlatinib takes CROWN in head-to-head comparison with crizotinib | Benjamin Solomon
ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study
ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study
Dr. Christine Lovly Discusses with #OncoAlert: The #CROWN study presented at #ESMO20 (Lung Cancer)
ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study
ESMO 2020 Highlights on pembrolizumab in LA-HNSCC: The GORTEC 2015-01 “PembroRad” study
ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005
ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study
ALTA-1L updates at ESMO 2020: intracranial efficacy and HRQoL
